Linked Life Data

20473593

Source:http://linkedlifedata.com/resource/pubmed/id/20473593

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2010-6-16
pubmed:abstractText
Angiogenesis plays an important role in the biology of hematological malignancies, including essential thrombocythemia (ET) and polycythemia vera (PV). Some data suggests that it has a role in the pathogenesis of thrombosis, the major clinical problem in ET and PV. The number of different subpopulations of circulating endothelial cells (CECs), plasma levels of vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor 1 and 2 (sVEGFR-1,2) and placenta growth factor (PlGF) were determined in 30 patients with ET and 16 patients with PV. Correlations between angiogenesis and JAK2-V617F mutational status, risk factors for thrombosis and coagulation activation markers were also assessed. The number of CEC subpopulations, were markedly higher in ET and PV patients, irrespective of JAK2-V617F status, when compared to the control group. The median values of activated CECs were markedly higher in PV patients with WBC >8.7 (x10(9)/l). Significantly higher VEGF plasma levels were found in ET patients and a similar trend was seen in PV patients in relation to healthy volunteers. The plasma levels of sVEGFR-1 were significantly higher, and PlGF levels markedly lower, in the ET and PV group than in controls. Our study also demonstrated markedly increased levels of D-dimer and TAT complexes in the patient groups. In conclusion, we found that angiogenesis, as measured by CEC numbers, is increased in ET and PV patients regardless of JAK2-V617F mutational status. Our results demonstrated that angiogenic cytokines interact with known thrombotic risk factors. We confirmed the coagulation activation in ET and PV patients but found no differences in levels of coagulation activation markers in relation to JAK2-V617F mutational status.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1865-3774
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
792-8
pubmed:meshHeading
pubmed-meshheading:20473593-Adult, pubmed-meshheading:20473593-Aged, pubmed-meshheading:20473593-Blood Coagulation, pubmed-meshheading:20473593-Endothelial Cells, pubmed-meshheading:20473593-Female, pubmed-meshheading:20473593-Humans, pubmed-meshheading:20473593-Janus Kinase 2, pubmed-meshheading:20473593-Male, pubmed-meshheading:20473593-Middle Aged, pubmed-meshheading:20473593-Mutation, pubmed-meshheading:20473593-Neovascularization, Pathologic, pubmed-meshheading:20473593-Polycythemia Vera, pubmed-meshheading:20473593-Pregnancy Proteins, pubmed-meshheading:20473593-Thrombocythemia, Essential, pubmed-meshheading:20473593-Vascular Endothelial Growth Factor A, pubmed-meshheading:20473593-Vascular Endothelial Growth Factor Receptor-1, pubmed-meshheading:20473593-Vascular Endothelial Growth Factor Receptor-2
pubmed:year
2010
pubmed:articleTitle
Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.
pubmed:affiliation
Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Ciolkowskiego 2, 93-510, Lodz, Poland. jtrel2001@yahoo.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't